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Abstract
The RGSZ2 gene, a regulator of G protein signaling, has been implicated in cognition, Alzheimer’s disease, panic disorder,
schizophrenia and several human cancers. This 210 amino acid protein is a GTPase accelerating protein (GAP) on Gai/o/z
subunits, binds to the N terminal of neural nitric oxide synthase (nNOS) negatively regulating the production of nitric oxide,
and binds to the histidine triad nucleotide-binding protein 1 at the C terminus of different G protein-coupled receptors
(GPCRs). We now describe a novel regulatory mechanism of RGS GAP function through the covalent incorporation of Small
Ubiquitin-like MOdifiers (SUMO) into RGSZ2 RGS box (RH) and the SUMO non covalent binding with SUMO-interacting
motifs (SIM): one upstream of the RH and a second within this region. The covalent attachment of SUMO does not affect
RGSZ2 binding to GPCR-activated GaGTP subunits but abolishes its GAP activity. By contrast, non-covalent binding of SUMO
with RH SIM impedes RGSZ2 from interacting with GaGTP subunits. Binding of SUMO to the RGSZ2 SIM that lies outside the
RH does not affect GaGTP binding or GAP activity, but it could lead to regulatory interactions with sumoylated proteins.
Thus, sumoylation and SUMO-SIM interactions constitute a new regulatory mechanism of RGS GAP function and therefore
of GPCR cell signaling as well.
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Introduction
The regulator of G protein signaling (RGS)17 protein, also
named RGSZ2, was initially described as a Gao subunit-
interacting protein [1], and subsequently, it was characterized as
a GTPase accelerating protein (GAP) of several classes of Ga
subunits, primarily Gi, Go, Gz, and Gq [2]. While no RGS
protein displays avidity for the inactive GaGDP form, most RGS
subfamilies exhibit weaker affinity for the GPCR-activated
GaGTP form than for the GTP hydrolysis transition state, where
GaGTPase initiates the conversion of GTP to GDP, [3,4]. The
RGS-Rz subfamily differs from other RGS proteins in that its
members, RGS17, RGS19(GAIP) and RGS20(Z1), exhibit
comparable avidities for both GaGTP and the transition state
forms [5]. Binding of the GPCR-activated GaGTP subunit to its
effectors generates this transition state and thus, the subunit is
allowed to reach and regulate the effector before the binding of
RGS proteins promote its deactivation. Thus, this unique
characteristic displayed by RGS-Rz proteins has led to the
proposal that they might fulfill an effector role [5]. Indeed, in brain
RGSZ2 behaves as an effector that binds the neural nitric oxide
synthase (nNOS) and negatively regulates the production of nitric
oxide (NO) that is induced by the Mu-opioid receptor (MOR)
agonist morphine [6].
The members of the RGS-Rz subfamily display notable
differences in their distribution. RGSZ1 is primarily expressed in
the brain [7,8], whereas GAIP is abundant in peripheral tissues
with only weak expression in the brain [9] and RGSZ2 is found in
various tissues, including the brain [2,10]. Interest in the
physiology of the RGSZ2 protein has increased in recent years,
particularly with a view to understanding the mechanisms
regulating its function to certain human cancers. The RGSZ2
gene is potentially behind the familial lung and bladder cancer
susceptibility locus on chromosome 6q23–25 [11,12], and the
RGSZ2 protein is over expressed in both human lung and prostate
cancer [13,14]. The RGSZ2 has also been implicated in human
cognitive ability [15], and the genome wide association database
relates this gene to Alzheimer’s disease, cerebral aneurysm,
narcolepsy, and panic disorder (https://gwas.lifesciencedb.jp/
cgi-bin/gwasdb/gwas_gene.cgi?name=RGS17). Indeed, 6q25 is
one of the most relevant schizophrenia-susceptibility locus on this
chromosome [16,17].
Although various RGSZ2 transcripts can be found in different
areas of the human brain, only a single transcript has been
detected in peripheral tissues [2]. Indeed, despite the numbers of
variants found, just two proteins are generated, each sharing a
common structure: a 210 residue RGSZ2 protein (NP_064342)
and a 230 residue RGSZ2 protein with a 20 amino acid extension
at the N terminus (NP_001155294). Below we shall consider the
different domains and regions of the 210 aa core RGSZ2
structure. This RGS protein contains a cysteine rich domain
(CRD) in its amino-terminus (residues 28–40) and the RGS box
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protein also contains several putative casein kinase 2 and PKC
phosphorylation sites, and a series of PDZ domain binding motifs
(61–64 MESI, 75–78 ADEV, and 76–79 DEVL) [2,6]. Moreover,
as described for other RGS-Rz member, GAIP [18,19], the
RGSZ2 could also attach to the cell membrane through
palmitoylation of the CRD. The RH domain of this protein binds
activated GaGTP subunits and regulates signaling at GPCRs,
acting as an effector antagonist [2,10,20]. RGSZ2 and RGSZ1
bind to the histidine triad nucleotide-binding protein 1 (HINT1) at
the MOR C terminus [21], and they contribute to the cross-
regulation of the MOR and the N-methyl-D-aspartate receptor
(NMDAR) [22]. By binding to the N terminus PDZ region of
nNOS, the PDZ binding motifs of RGSZ2 serve to regulate the
production of NO and the release of zinc from intracellular stores,
thereby contributing to the activation of the glutamate-regulated
NMDAR [6,23]. In analogy to the previously described for
RGSZ1 and GAIP, the RGSZ2 also is thought to interact with
proteins such as SCG-10, synapsin-1a, GIPN [24–26]. As such,
the RGSZ2 protein plays essential roles in regulating cell signaling
through both metabotropic and ionotropic NMDA receptors.
The regulation of RGS GAP activity by post-translational
modifications such as phosphorylation of RH critical residues, and
to a minor extent palmitoylation is a relatively common process
[27]. However, little is known about the cellular regulation of the
multifaceted RGSZ2 protein. The presence of the RGSZ2 protein
in neuronal nuclei suggests a regulatory role for this protein in
gene transcription [28] and also opens the possibility that a novel
mechanism, incorporation of Small Ubiquitin-like MOdifiers
(SUMO), regulates its function. Sumoylation of proteins is a
reversible modification that mechanistically resembles ubiquitina-
tion and that alters the activity of a broad range of (primarily
nuclear) proteins [29]. Therefore, we considered it interesting to
analyze the capacity of RGSZ2 to incorporate SUMO and how
this covalent attachment would influence its GAP activity on
GPCR-activated GaGTP subunits. Our results indicate that
RGSZ2 co-localizes with GPCRs in the cell membrane where it
can regulate the strength of the signals transduced by these
receptors. Moreover, RGSZ2 GAP activity is finely regulated
through the covalent attachment of SUMO in its RH domain, and
by SUMO-interacting motifs (SIMs) that non-covalently bind
SUMO.
Results
RGSZ2 contains a single SUMO attachment site and two
SUMO-interacting motifs
The RGSZ2 protein contains 210 residues with a cysteine-rich
domain in its amino-terminus (residues 28 to 40; 9 of 13 total
residues are cysteine), a series of PDZ binding motifs (residues 61–
64 MESI, 75–78 ADEV, and 76–79 DEVL) which binds to the
nNOS PDZ domain [6], and the typical nine alpha helices of the
RH domain (residues 80 to 190) (Fig. 1A). We had previously
observed forms of the 24 kDa RGSZ2 protein that could be
sumoylated in brain synaptosomes [6,28]. Therefore, we consid-
ered of interest to address the impact of sumoylation on the
RGSZ2 GAP activity. The RGSZ2 sequence predicts that, in
addition to a sumoylation consensus site at the end of the a4R H
box (K121 in LKKE: Fig. 1A, http://www.abgent.com/doc/
sumoplot), RGSZ2 contains two putative SUMO-interacting
motifs (SIMs): one before the RH, IQVL (64–67), and the other
at the end of a5 RH, ISIL (141–144). A typical SIM consists of a
hydrophobic box of four aliphatic residues with the consensus
sequence Val/Ile-X-Val/Ile/Leu-Val/Ile/Leu (V/I–X–V/I/L–
V/I/L), juxtaposed to a negatively charged cluster. This structure
allows the hydrophobic residues in SUMO, the b-grasp fold, and
the neighboring positive charge to interact with the SIM [30–33].
To confirm that the predicted RGSZ2 sumoylation site was
functional, we reconstructed the sumoylation pathway in Esche-
richia coli to obtain recombinant sumoylated proteins. The
machinery was composed of human SUMO1, human Aos1,
human Uba2, murine Ubc [34], as well as the target proteins
RGSZ2 or its RH region. The SUMO1/2/3 proteins range from
10 to 12 kDa, and only the SUMO2/3 isoforms form polymeric
SUMO chains [35]. To avoid branching, we restricted our
analysis to the incorporation of SUMO1. Then, GST-RGSZ2 and
GST-RGS box were co-expressed with the SUMO1 machinery.
Afterwards, they were cleaved by TEV protease and GST
removed. The SDS-PAGE analysis revealed that RGSZ2 and its
RH incorporated a SUMO1 molecule, as indicated by a molecular
weight shift of approximately 11 kDa and their recognition by
anti-SUMO1 antibodies (Fig. 1B). No incorporation of SUMO1
was detected in a K121R RGSZ2 mutant (Fig. 1C) -evidence that
the sumoylation site found in the RGS box is unique. The anti-
RGSZ2 antibodies used in this study were purified and
characterized by affinity binding against their antigenic peptide
sequence, followed by their binding to the recombinant RGSZ2
protein ([6]; and Fig. S1).
We tested the possibility of a sumoylated protein to interact with
a SIM located on the RGSZ2 protein. Thus, agarose conjugated
SUMO1, SUMO2 or SUMO3 exhibited non-covalent binding to
RGSZ2 or its RH region (Fig. 2A). However, the Gai2 subunit
which contains two putative SIMs (VKLLL, residues 34 to 39;
IILFL, residues 265 to 269) did not show stable binding to these
SUMO variants (Fig. 2B). The RGSZ2 SIMs are juxtaposed to a
negatively charged cluster and showed a notable avidity for its
interaction with SUMO. In contrast, those on the Gai2 protein
lack the requested negative surrounding and the interaction was
probably weak being disrupted during the precipitation procedure.
From these assays we concluded that the RH, which is essential for
binding to Ga subunits, contains at least one SIM able to bind to
SUMO1, confirming computer-based predictions and the SUMO-
SIM interactions in trans. The influence of the covalent
incorporation of SUMO1 on the binding of the RGSZ2 RH to
activated Ga subunits was evaluated by pull-down assays. It was
observed that both RGSZ2 and its sumoylated form bound to Ga
in the transition state (GDP + ALF4
-). However, they bound
poorly or not at all to GaGDP (Fig. 3). Thus, the RGS-attached
SUMO1 did not prevent RGSZ2 from binding to the activated
Ga subunits.
The effects of SUMO and SUMO-SIM interactions on
RGSZ2 GAP activity
Because covalently attached SUMO1 did not significantly alter
the capacity of RGSZ2 to bind activated Ga subunits, we analyzed
whether this modification affects its GAP activity by measuring the
hydrolysis of GTP by Gai in single-turnover assays with one cycle
of Pi production. In the experimental conditions studied, the kcat
observed for recombinant Gai was about 2.2 min
21, a value in the
range described for recombinant Gai/o proteins [36]. Recombi-
nant RGSZ2 displayed concentration-dependent GAP activity on
the Gai-associated GTPase (Fig. 4A), and the sumoylated RGSZ2
did not significantly alter the basal GTPase activity (Fig. 4B).
However, in steady-state assays in which n cycles of Pi production
would be expected to occur, sumoylated RGSZ2 blocked Pi
production (Fig. 4C). This result indicates that sumoylated RGSZ2
proteins bind to activated GaiGTP subunits but that they display
weak or no GAP activity on the GaiGTPase. Moreover, the
RGSZ2 SUMO-SIM Interactions
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subunits so that GDP could be exchanged for GTP and thus, the
production of Pi diminished.
To evaluate the influence that the non-covalent binding of
sumoylated proteins to RGSZ2 SIMs could have on the GAP
activity of RGSZ2, GTPase assays were performed in the presence
of free SUMO1 (Fig. 5A). RGSZ2 and SUMO1 were used at
equimolar concentrations. It was observed that SUMO1 interfered
with RGSZ2 GAP activity without modifying the basal GTPase
activity of Gai. Similar results were obtained for free SUMO1 and
the GAP activity of the RGSZ2 RH region or the mutated K121R
RGSZ2 which does not incorporate covalently SUMO. However,
in contrast to what was observed in the steady-state assay with
sumoylated RGSZ2 protein, the RGSZ2 in the presence of free
SUMO1 did not diminish Gai-mediated Pi production. These
data imply that free SUMO binds to the SIM inside the RGSZ2
RH and then reduces its GAP activity or simply prevents the
access of the activated Ga subunit, leading to no detectable GAP
activity.
These possibilities were evaluated by analyzing the influence of
free SUMO1 on RGSZ2 GAP activity and Ga binding to the RH
region. In single turnover assays, increasing concentrations of
SUMO1 decreased the extent of RGSZ2-Gai2 association
(Fig. 5B). Thus, the blocking effect of free SUMO1 on RGSZ2
GAP activity correlated with a reduction in its avidity for the Ga
subunit. The involvement of SIM (residues 141 to 144) in this
Figure 1. RGSZ2 contains a SUMO-attachment site and SUMO-interacting motifs. A, Protein domains of the murine RGSZ2 protein
(NP_064342). The cysteine- rich domain (CRD) is underlined, the RH domain (RGS box) is shaded in gray and the a-helical residues of the secondary
structures are indicated. The Small Ubiquitin-like Modifier (SUMO) consensus motif is in bold-italics, with lysine121 enlarged-underlined, SUMO-
Interacting Motifs (SIMs) are in bold, indicating the clusters of negative amino acids surrounding the SIMs. The PDZ domain binding motifs (PDZ bm)
are also indicated. Below, a diagram of the RGSZ2 protein indicates the position of the cysteine-rich domain, RH region, SUMO covalent modification
K121 (LKKE), non-covalent SIM IQVL (64–67) and ISIL (141–144). B. The RGSZ2 and the RH region were cloned into E. coli BL21 (DE3) with or without
the SUMO machinery [34]. GST-free RGSZ2 proteins (TEV cleavage) were resolved by SDS-PAGE, and probed with anti-RGSZ2 and anti-SUMO1
antibodies. Lane 1: control (no RGSZ2 vector); lane 2: RH region; lane 3: whole RGSZ2 sequence. C. The K121R RGSZ2 mutant induced along with the
SUMO machinery was not sumoylated. Assays were repeated at least twice and produced comparable results. Representative experiments are shown.
doi:10.1371/journal.pone.0028557.g001
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RGSZ2 mutants in the presence of free SUMO1. Although wild-
type RGSZ2 increased GTPase activity, this increase was
prevented by SUMO1. However, the I141N, I143S and L144Q
RGSZ2 missense mutants all displayed increased GTPase activity
independently of the presence of free SUMO1 (Fig. 6A). We noted
that the I143S RGSZ2 mutant continued to co-precipitate with
SUMO proteins, which indicated the presence of at least one other
SIM in the RGSZ2 molecule (Fig. 6B). By contrast, the
V66D+I143S RGSZ2 double mutant did not associate with
SUMO (Fig. 6C). Thus, RGSZ2 appears to have two SIMs, one
upstream of the RH and another within the RH region (Fig. 1A).
The effect of SUMO-SIM interactions on the cellular
distribution and activity of endogenous RGSZ2
We analyzed whether the cellular distribution of RGSZ2 is
consistent with its proposed role in regulating GPCR signaling.
RGSZ2 mRNA was detected in the mouse brain and in CHO cells
(Fig. 7A). The RGSZ2 was found in dense puncta along the
plasma membrane (Fig. 7B & 7D), pattern that is compatible with
RGSZ2 regulating GPCR function. The RGSZ2 protein is a
24 kDa protein but when resolved by SDS-PAGE, the endogenous
protein is typically detected as a ladder with a series of higher
molecular weight isoforms [10,37]. As observed in the CNS, the
RGSZ2 protein from CHO cells also resolves as a ladder and the
24 kDa RGSZ2 can barely be detected. Significantly, all these
bands were sensitive to specific siRNA’s when analyzed by SDS-
PAGE gel chromatography, indicating they are related to RGSZ2
(Fig. 7C & 7D).
Thus, the covalent attachment of SUMO to the neural RGSZ2
protein seems to account for the different sizes of this protein
observed in SDS-PAGE. Considering that sumoylation alters the
activity of a broad range of proteins [29], we analyzed the
influence of this modification on the regulation of neural RGSZ2
on activated GaGTP subunits. Accordingly, the neural RGSZ2
protein was enriched by affinity chromatography using agarose-
coupled antibodies purified against peptide sequences from this
RGS. In the absence of reducing agents, the neural RGSZ2
protein was hardly evident when the proteins recovered were
resolved by SDS-PAGE (Fig. 8A, control lane). The SENP family
of proteases produces some degree of protein de-sumoylation [38],
and when the material pulled down by RGSZ2 antibodies was
exposed to the action of the SENP1 and SENP2 proteases,
RGSZ2 isoforms became visible in the gels, including the 24 kDa
form. The presence of lower molecular weight bands after SENP
treatment confirmed that RGSZ2 is mostly present in cells as a
heavily sumoylated protein containing strings of SUMO2/3 [28]
attached to the K121 site in the RH domain.
The effect of sumoylation on neural RGSZ2 GAP activity was
addressed by measuring its influence on the rate of [c-
32P]GTP
hydrolysis at Ga subunits (Fig. 8B). In single turnover assays Gai
hydrolysis of [c-
32P]GTP followed an exponential time-course and
while the addition of sumoylated neural RGSZ2 did not affect the
rate of Gai hydrolysis, the treatment of this material with the
Figure 3. Influence of SUMO on Gai subunit association with
RGSZ2 proteins. Binding of
35S-Gai to sumoylated and unsumoylated
recombinant RGSZ2 proteins. In vitro-translated
35S-labeled GaiGDP
subunits (10 ml) were incorporated into the samples, alone or with
2 mM MgCl2 and 30 mM AlF4- (30 mM AlF3 + 30 mM NaF). Samples in
lanes 1 and 2 received glutathione sepharose (GS) beads; lanes 3 and 4,
GST-RGSZ2 protein bound to GS beads; lanes 5 and 6, sumoylated GST-
RGSZ2 attached to GS beads. Lanes 2, 4 and 6, 2 mM MgCl2 and 30 mM
AlF4- were added to the incubation mixture. Lane 7 shows the Gai,
which was added to the samples analyzed in lanes 1 to 6. At the end of
2 h incubation, GS beads were precipitated and washed; RGSZ2-Gai
association was determined by autoradiography.
doi:10.1371/journal.pone.0028557.g003
Figure 2. Sumo binds non covalently the recombinant RGSZ2
protein. A. Recombinant RGSZ2 and its RH region were incubated with
SUMO1- (lane 3), SUMO2- (lane 4) and SUMO3-agarose (lane 5). SUMO-
agarose conjugates captured RGSZ2 and its RH domain. Lane 1, RGSZ2/
RH added. Lane 2, RGSZ2/RH in presence of agarose without SUMO.
B. The Gai2 subunit shows no binding to SUMO1/2/3-agarose.
doi:10.1371/journal.pone.0028557.g002
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from GTP hydrolysis. Thus, increased GAP activity was linked to
reductions in the amount of sumoylated RGSZ2. Indeed, in a
steady-state GTPase assay in which GaGTPase activity depended
not only on GTP hydrolysis but also on GDP/GTP exchange,
sumoylated neural RGSZ2 decreased the Ga-mediated produc-
tion of Pi in accordance with the results obtained for sumoylated
recombinant RGSZ2 (see Fig. 4C). SENP2 treatment reversed this
effect and increased the rate of GTP hydrolysis. These
observations indicate that the sumoylated neural RGSZ2 protein
Figure 4. Effect of covalent sumoylation of RGS box on the GAP activity of RGSZ2 proteins. A. RGSZ2 GAP activity. In the single turnover
assay, 100 nM Gai was incubated with 30 or 200 nM of RGSZ2. The estimated kcat (min
21) for Gai when alone was 2.2; while in the presence of 30nM
and 100nM RGSZ2 it was 4.4 (kgap=2.2 min
21) and 8.0 (kgap=5.8 min
21), respectively. The maximal release of Pi in these experimental conditions
was about 1.1 pmol. *Significantly different from the value for Gai alone; P,0.05. B. The effect of covalent attachment of SUMO1 on RGSZ2 GAP
activity. Sumoylated RGSZ2 (200 nM) shows no GAP activity on 100 nM Gai subunits in the single turnover assay, kgap=0.1 min
21. C. Sumoylated
RGSZ2 blocks the liberation of Pi generated by Gai GTPase in the steady-state. *Significantly different from the value for Gai alone; P,0.05. For all
assays, triplicate samples were collected at the intervals indicated and transferred to charcoal quenching solution. The values at time 0 were
subtracted. Assays were repeated twice and the results were comparable.
doi:10.1371/journal.pone.0028557.g004
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PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e28557Figure 5. Non-covalent interaction of free SUMO1 abolishes RGSZ2 GAP activity. A. In single turnover and steady-state GTPase assays, the
endogenous GTPase activity of 100 nM Gai subunits was unaffected by 500 nM free SUMO1 in the medium, which nonetheless inhibited the GAP
activity of 200 nM RGSZ2. The kcat values (min
21) were: Gai alone =2.1, Ga1 + SUMO1=2.0, Gai + RGSZ2=7.9, Gai + RGSZ2 + SUMO1=2,4. Free
SUMO1 also impairs the GAP activity of the RGSZ2 RH domain. In single turnover assays of GTP hydrolysis by Gai, the RH region shows GAP activity on
Gai subunits. This activity was blocked by the addition of SUMO1 to the medium. The kcat values (min
21) were: Gai alone =2.2, + RGSZ2 RH =4.0, +
RGSZ2 RH and SUMO1 =2.5. The RGSZ2 K121R mutant acts as a GAP on Gai subunits, which is blocked by free SUMO1 in the medium. The kcat values
(min
21) were: Gai =2.0, + K121R RGSZ2 =6.9, + K121R RGSZ2 + SUMO1 =2.1. *Significantly different from the value for Gai alone; P,0.05.
B. Concentration-dependent inhibition of RGSZ2 GAP activity by free SUMO1 -single turnover assay. The Gai subunits were loaded with GTPc
32P
alone or with RGSZ2 and increasing concentrations of SUMO1. The Pi release was determined 60 s after GTPase activation. *Significantly different
RGSZ2 SUMO-SIM Interactions
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GAP activity on them, rather it delays the release of GaiGDP
subunits and impedes correct GTPase activity at the Ga subunits.
Discussion
It is becoming frequently acknowledged that RGS proteins
display a more complex role in cellular signaling than that
expected for a GAP of activated GaGTP subunits. This is
particularly notable for large RGS proteins in which the RH
domain is just one of several protein interacting motifs. However,
in RGSZ2 the RH domain represents half the total protein size
but still, this RGS protein interacts with distinct proteins to
regulate the activity of GPCRs (see Introduction). The present
study indicates that the GAP activity and associated functions of
RGSZ2 can be regulated by a novel mechanism, the covalent
sumoylation of its RH domain, in concert with non-covalent
interactions of SUMO-containing proteins at two SIMs: one
within and the other outside of the RGSZ2 RH region.
The regulation of RGS RH GAP activity by post-translational
modifications is a relatively common process. Phosphorylation of
critical residues in the RH domain, and to a minor extent
palmitoylation, can modify the GAP activity of these proteins [27].
Indeed, the GAP activity of the RGS-R7 subfamily is modulated
dynamically by tumor necrosis factor-a which promotes the
phosphorylation-dependent binding of 14-3-3 proteins [39].
Binding of 14-3-3 inhibits RGS-R7 GAP function and it is
mediated by a conserved phosphoserine located in the Ga-
interacting region of the RH domain [40]. Therefore, phosphor-
ylation, palmitoylation, and now sumoylation can act as molecular
switches to reduce or even abolish RH GAP activity. Such
functional modifications may serve regulatory purposes and
indeed, the non-covalent binding of SUMO to the RGSZ2 RH
SIM located at residues 141–144 abrogates its interaction with
GaGTP subunits. By preventing RGSZ2-GaGTP binding, this
particular SUMO-SIM interaction enhances the signaling of the
regulated GPCR to its effectors.
Notably, modified RH domains and proteins containing RH-
like domains that can bind to GaGTP subunits but exhibit little or
no GAP activity on them reduce the signaling capacity of GPCRs
[41]. This is a process referred to as effector antagonism, and it is
observed for GRK2 and GRK3, proteins that carry RH domains
displaying little or no GAP activity but that sequester activated
GaqGTP subunits, thereby attenuating the activation of PLCb
and reducing the signaling capacity of the corresponding GPCR
[42]. Another example is the RH of Axin which binds to
Ga12GTP subunits without affecting intrinsic GTP hydrolysis of
Ga12, although it competes for binding to the RH domain of
G12-interacting proteins, such as p115RhoGEF [43]. Accordingly,
the persistent binding of the sumoylated RGSZ2 RH domain to
effector active GaGTP subunits could be considered as effector
antagonism as it delays their return to the control of the GPCR,
reducing its signaling capacity [2,10,20]. In fact, morphine
promotes the PKC-dependent transfer of MOR-regulated Ga
subunits to RGSZ2 proteins, subsequently reducing the analgesic
effects of opioids [10,20]. Notwithstanding, RGSZ2 itself is as an
effector of GPCR-activated GaGTP subunits. When the RGSZ2
RH domain remains bound to activated GaGTP subunits, this
activity triggers the PKC-mediated separation of the RGSZ2-
nNOS complex from the HINT1 protein [22], and the subsequent
GaGTP.RGSZ2-mediated regulation of nNOS [6].
Sumoylation is widely considered as a nuclear or perinuclear
phenomenon, as SUMO is covalently linked to many nuclear
proteins, however, there is increasing evidence that plasma
membrane proteins can also be modified in this manner [44,45].
Examples of non-nuclear sumoylated proteins include Axin [46], the
phosducin regulator of Gbc signaling [47] and the RGS-Rz proteins
that regulate Ga subunits [28]. These proteins may be subject to
nucleocytoplasmic cycling facilitating their sumoylation in the
nucleus, at nuclear pore complexes or even in the cytoplasm
[48,49], before they are transported to the cytosol and/or cell
membrane. The RGSZ2 proteins probably undergo sumoylation in
the nuclear fraction [28] prior to their transport to the neuronal
membrane, where they through SUMO-SIM interactions influence
GPCR signaling. In the SUMO-SIM interaction the SUMO protein
folds into a complex structure that buries the hydrophobic SIM
residues in a surface cleft, an interaction that is stabilized by hydrogen
bonds between SIM residues and SUMO surface side chains [30].
The neighboring positive charge of SUMO interacts with the
accessory negatively charged SIM cluster [30–33]. The quality of this
ionic interaction is decisive in stabilizing the SUMO-SIM interaction,
which may be almost irreversible, and it probably requires
phosphorylation to disrupt the complex. Indeed, strong SUMO-
SIM interactions have been observed through pull-down assays [50]
that were absent when the putative SIM domains lacked the required
accompanying negative sequence (e.g., the Gai2 subunit).As such, the
reported affinity equilibrium constants (KD) of about 1–3 mMd on o t
reflect a situation in which the strength of the SUMO-SIM
interaction greatly reduces their spontaneous dissociation.
The presence of covalent SUMO modifications and of SIMs in
the same molecule could lead to SUMO-SIM interactions
assembling high-order protein complexes. This has been elegantly
described for the promyelocytic leukemia protein (PML) that
contains conjugated SUMO and SIM domains capable of
promoting the formation of PML nuclear bodies [51]. The heavy
sumoylation of RGSZ2 proteins has been confirmed using SENP
proteases, which hydrolyze SUMO conjugated to target proteins,
although these proteases only partially remove branched SUMO
residues from proteins in vitro [38,52,53]. Both SUMO2 and
SUMO3 also participate in neural RGSZ2 protein sumoylation
[28] and these SUMO variants can form poly-SUMO chains that
enhance the probability of interactions with SIM-containing
proteins. Indeed, these variants could also participate in the
recruitment of RGSZ2 proteins into protein complexes, as
observed for SUMO-SIM interactions that regulate the association
between critical nuclear proteins [54]. Accordingly, non-covalent
binding of SUMO to RGSZ2 SIM 64–67 outside the RH should
not affect Ga binding or RGSZ2 GAP activity but rather, these
interactions could facilitate the role of RGSZ2 proteins as a
scaffold, thereby influencing GPCR signaling [2,10,28].
In summary, SUMO-SIM interactions serve to localize and
target proteins, as well as to modify protein function, as described
here for the RGSZ2 protein. The covalent attachment of SUMO
switches the activity of the RGSZ2 RH from that of a GAP of
activated GaGTP subunits to that of an effector recognition site
for GPCR-regulated Ga subunits. While the GAP and effector
activities can be regulated through SUMO-SIM interactions at the
RGSZ2 RH domain, those outside the RH preserve its GAP
activity, probably contributing to the formation of RGSZ2
nucleated protein complexes. Thus, the influence of RGSZ2
proteins on GPCR signaling can be precisely and efficiently
from the value for Ga alone; P,0.05. Inset: At 60 s after initiation of the reaction, RGSZ2 was immunoprecipitated (IP; CT antibody) and the associated
Gai proteins were analyzed in Western blots probed with an anti-Gai antibody.
doi:10.1371/journal.pone.0028557.g005
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novel process may affect the contribution of RGSZ2 to the critical
events in which it is involved.
Materials and Methods
Reagents
The phosphatase inhibitor cocktail, H89, polyoxyethylene10
lauryl ether (C12E10), phenylmethylsulphonyl fluoride (PMSF),
leupeptin, aprotinin NP-40 and the protease inhibitor cocktail were
obtained from Sigma. The Western blot Chemiluminescent HRP
substrate was from GE Healthcare (RPN232), and Gai were from
Calbiochem. Small interfering RNAs (siRNA; sc-29528) against
RGSZ2 (sc-61467), control siRNA (scRNA; sc-37007), fluorescein-
conjugated control siRNA (sc-36869) were purchased from Santa
Cruz Biotechnology, and SENP2 [368–549] fragment, GST-tagged
(human, recombinant) was from Enzo Life Sciences (UW9765).
Animals
Male albino CD-1 mice weighing 22–25 g were housed and
used strictly in accordance with the European Community
guidelines for the Care and Use of Laboratory Animals (Council
Directive 86/609/EEC). The experimental protocols were
reviewed and approved by the Committee for Animal Experi-
mentation at the CSIC.
Antibodies
Affinity-purified IgGs against the antigenic peptide: anti-
RGSZ2 CT (C terminus amino acids 192–215), antibodies against
peptide sequences in the Ga helical domain of Gai2, have been
described elsewhere [55,56]. The anti-RGSZ2 W15 was pur-
chased from Santa Cruz (sc-48286) and an anti-RGSZ2 IQ
(internal sequence) was raised against the murine amino acid
sequence 46–60 (GenScript, Piscataway, NJ). The anti-SUMO1
was obtained from Cell Signaling Technology. All primary
antibodies were detected using the appropriate horseradish
peroxidase-conjugated secondary antibodies.
Preparation of synaptosomal membranes
The periaqueductal gray matter (PAG) and cortex from cohorts
of 6-10 mice were homogenized (Polytron) in 25 mM Tris-HCl
[pH 7.4], 0.32 M sucrose, H89, protease and phosphatase
inhibitor cocktails. Homogenates were centrifuged (1000xg) to
obtain post nuclear-supernatants (S1), which were processed to
prepare synaptosomes. The synaptosomal pellet was resuspended
in 50 mM Tris-HCl [pH 7.7] supplemented with 2mM PMSF,
2 mg/mL leupeptin and 0.5 mg/mL aprotinin. The membranes
were aliquoted and frozen at 280uC.
Preparation of endogenous RGSZ2 proteins by
immunoaffinity chromatography
Synaptosomal membranes P2 were thawed and sonicated (two
cycles of 5 s each) in a buffer containing 50 mM Tris-HCl
Figure 6. The RH domain SIM (141–144) binds SUMO1 and
blocks RGSZ2 binding to Ga subunits. A. Disruption of the SIM
(141–144) by mutation reverses free SUMO-mediated steric hindrance
of RGSZ2-Gai binding. The I141N, I143S and L144Q RGSZ2 mutants
displayed GAP activity on Gai, even in the presence of 1 mM free
SUMO1. *Significantly different from the value for Ga alone; P,0.05.
B. SUMO proteins bind the I143S RGSZ2 mutant but not the double
V66D+I143S mutated RGSZ2 (C), indicating the presence of a second
SIM upstream of the RGS box (see Fig. 1A).
doi:10.1371/journal.pone.0028557.g006
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and protease inhibitor cocktail and H89. The proteins were then
heated for 10 min at 40uC in 40mM Tris-HCl, 2% SDS buffer,
cooled to room temperature and filtered (0.22 mm). The SDS
concentration was reduced by adding octylthioglucoside to a final
percentage of 0.65% and the samples were incubated overnight
Figure 7. RGSZ2 mRNA and protein expression in mouse brain and CHO cells. A. Identification of RGSZ2 mRNA in mouse brain and CHO
cells. One hundred nanograms of total RNA isolated from (1) mouse brain and (2) CHO cells were used for RT-PCR analysis. Arrows indicate the bp PCR
product of RGSZ2 obtained using alternative primers pair PP1 & PP2, see Methods. DNA Ladders: 1550, 850, 400, 200; 1031, 900, 800, 700, 600, 500,
400, 300, 200 bp. The CHO 464 bp product (2) has been intensified. B. Light micrographs taken from coronal sections through the cerebral cortex (I)
and PAG (II) illustrating the localization of the RGSZ2 immunoreactivity (IQ antibody). I, shows labeled neurons pyramidal in shape in layer V of the
cerebral cortex. II, represents strong immunostaining labeling cells (arrows) and processes in the PAG. Aq: midbrain aqueduct. C. Reduction of RGSZ2
mRNA expression. Confluent CHO cells (80–90%) were transfected with control siRNA or siRNA. Total RNA was extracted, retrotranscripted to cDNA
and mRNA expression of RGSZ2 gene analyzed by real-time PCR. GAPDH gene expression was used as internal standard. Bars are the mean + SEM of
RGSZ2 mRNA expression as percentage of control cells without being transfected. *Significantly different from the control siRNA, P,0.05.
D. Reduction of RGSZ2 mRNA expression brings about decreases in the levels of the encoded protein (IQ antibody). For western blot assays CHO cells
were solubilized in Laemmli buffer with reducing agents. Immunocytochemistry of CHO endogenous RGSZ2. Nuclei stained with DAPI in blue. The
diminishing effect of siRNA on CHO cells RGSZ2 expression was analyzed 48 h after transfection.
doi:10.1371/journal.pone.0028557.g007
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Flow beds (GE Healthcare Bio-Sciences). After washing, the
immune complexes were collected by an acid wash (100 mM
Glycine-HCl [pH 3]), neutralized to pH 7.5 and the buffer was
exchanged for a GTPase assay buffer. This procedure yielded
RGSZ2 protein as verified by silver staining and Western blot
analysis [28]. Incubation of the mSENP2 homologue that cleaves
SUMO1, 2, and 3 conjugates, was used to remove SUMO from
the immunoprecipitated RGSZ2.
Expression of recombinant proteins in Escherichia coli
and the sumoylation of RGSZ2 proteins
Murine full-length RGSZ2 (NM_019958) and its RGS box were
cloned by PCR from PAG cDNA. Glutathione S-transferase
(GST) fusion proteins were obtained by cloning mRGSZ2 and its
RGS box into the pFN2A (GST) Flexi vector (Promega). The
vector was introduced into E. coli BL21 (KRX, Promega, #L3002)
and clones were selected on solid medium containing ampicillin.
Bacterial lysates containing GST fusion proteins were immobilized
on glutathione-Sepharose 4B columns (Amersham Biosciences),
the GST was clipped off with ProTEV protease (Promega) and the
GST-free proteins were concentrated. Finally, the TEV protease
was removed by affinity chromatography.
Site directed mutagenesis was performed with Accuprime Pfx
DNA Polymerase (Invitrogen) using pFN2AmRGSZ2 as the
template. Lys 121 was mutated to Arg (K121R), Ile 141 to Asp
(I141N), Ile 143 to Ser (I143S) and Leu 144 to Gln (L144Q) the
amplified fragment was digested with NcoI and BamHI enzymes and
cloned into pFN2A (GST) FlexiH Vector (Promega, Madison, WI,
USA). To generate the I143S, V66D RGS17 double mutant PCR
amplification was performed using as a template the plasmid
pFN2ARGSZ2I143S. The sequences of the plasmids and the
K121R, I141N, I143S, L144Q point mutations and I143S - V66D
doublemutationswereconfirmedbyautomatedcapillarysequencing.
For Sumoylation of recombinant RGSZ2, its RGS domain and
K121R RGSZ2, the RGSZ2-containing vectors were electroporat-
ed into E. coli BL21 (DE3) alone or with a polycistronic pBADE12
vector encoding Aos1, Ubc9, Uba2 and pKRSumo1[34]. Trans-
fected clones were selected on solid medium containing kanamycin,
choramphenicol and ampicillin. Sumoylated proteins were resolved
on 4–12% NUPAGE Bis-Tris gels (Invitrogen) and transferred to
PVDF membranes that were probed with antibodies against
SUMO1 or RGSZ2.
SUMO and Ga subunit binding to RGSZ2 proteins
RGSZ2 (WT or RH domain) were incubated in 50 mM
HEPES [pH 8.0], 1mM EDTA, 1 mM DTT, 0.05% C12E10 (for
Figure 8. RGSZ2 GAP activity after SUMO removal. A. Effect of
SUMO removal by SENP1 or SENP2 on neural RGSZ2 protein. RGSZ2
from SDS-octylthioglucoside solubilized synaptosomal membranes was
retained by the NHS-agarose-coupled RGSZ2 antibody IQ. Affinity-
purified RGSZ2 proteins were incubated alone (lane 1) or with proteases
that remove SUMO (lanes 2 & 3). SENP1 preferentially removes SUMO1
whereas SENP2 removes SUMO1, SUMO2 and SUMO3. The samples
were then solubilized in Laemmli buffer without reducing agents. In its
absence and without SENP treatment, RGSZ2 heterocomplexes hardly
enter the gel (lane 1). The anti-RGSZ2 CT was used to detect those
signals. B. Sumoylated neural RGSZ2 protein lacks GAP activity but this
is restored by SENP2 treatment. The observed kcat (min
21) were: Gai
alone =2.1; in the presence of endogenous RGSZ2 =1.8; and of SENP2-
treated endogenous RGSZ2 =s.7. Data are the mean 6 S.E.M. of
triplicate samples collected at the intervals indicated. *Significantly
different from the value for Gai alone; P,0.05.
doi:10.1371/journal.pone.0028557.g008
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agarose (BIOMOL). After washing, the beads were boiled in
sample buffer, and the proteins were separated by SDS-PAGE and
then transferred to PVDF membranes. The RGSZ2 bound to
SUMO-agarose was determined by immunoblotting, detecting the
anti-RGSZ2 with an HRP-conjugated anti-rabbit antibody.
Chemiluminescence was recorded with a ChemiImager IS-5500
(Alpha Innotech, San Leandro, CA).
GTPase assays
For single turnover GTP hydrolysis, 100 nM Gai was loaded
with 1 mM GTP plus 0.4 nM [c-
32P]GTP (6,000 Ci/mmol, Perkin
Elmer) for 30 min in 50 mM HEPES [pH 8.0], 5 mM EDTA,
1 mM DTT, and 0.05% C12E10 at 30uC, after which the
reaction mixture was shifted to 17uC. Reactions were initiated by
adding a RGS mix consisting of 15 mM MgSO4, 150 mM GTP,
0.5 mM SUMO1 (BIOMOL) and/or 0.2 mM RGSZ2 protein
(neural or recombinant), and the reactions were then quenched by
adding charcoal, as described [24]. In blanks (without Ga
subunits), 1–2% of total radioactivity added was evident as the
background. Data were fitted to a single exponential curve
(Sigmaplot v12, Systat Software, Inc. Germany) to obtain the GTP
hydrolysis rate constant of the Gai in the absence and in the
presence of the potential modifier, e.g., RGSZ2 variants and
SUMO1. RGS protein-dependent Gai GTPase activity (kgap) was
defined as [kcat(Gai basal+RGS) - kcat(Gai basal-RGS)] [57,58].
Steady-state GTPase activity was measured as described
elsewhere [59]. Briefly, heterotrimeric G proteins or Ga subunits
plus SUMO1 and/or RGSZ2 proteins (neural or recombinant)
were added to the reaction mixture containing 1 mM GTP plus 0.4
nM [c-
32P]GTP in 50 mM HEPES [pH 8.0], 1mM EDTA,
1 mM DTT, 15 mM MgSO4 and 0.05% C12E10, which was
then incubated for 0–20 min at room temperature. The reaction
was terminated by adding charcoal and the associated radioactiv-
ity was counted as above.
RGSZ2 protein expression and mRNA
Deeply anaesthetized animals (Equithesin, Janssen Laborato-
ries, 2.5 mL/kg intraperitoneally) were ventilated and perfused
through the left ventricle with 0.9% saline followed by 250 mL
of a fixative solution containing 4% paraformaldehyde in 0.1 M
phosphate Buffer (PB), pH 7.4 After fixation and cryoprotection,
serial 40 mm thick transverse frozen sections were cut with a
2800 Frigocut (Reichert-Jung) microtome and then processed.
Immunohistochemistry for RGSZ2 was carried out in free-
floating sections that were preincubated in 1% H2O2 in PBS for
one hour to inactivate endogenous peroxidase. Sections were
then treated with 3% normal goat serum, for 1 h at RT. After
washing in PBS, the sections were incubated overnight at 4uC
using the anti-RGSZ2 antibody IQ diluted (1:500) in phosphate-
buffered saline (PBS) containing 0.2% Triton X-100. After
washing thoroughly in PBS, histological sections were incubated
with biotinylated secondary goat anti-rabbit immunoglobulins
diluted 1:200 (Vector Laboratories, Burlingame, CA, USA) for
1 h at RT. After additional washes, sections were incubated with
peroxidase-linked ABC (Vector Laboratories) for 90 min [60].
Peroxidase activity was developed as described [61]. Briefly,
sections were preincubated in a histochemical medium that
contained 0.06% 3,39-diaminobenzidine tetra HCl (DAB,
Sigma, St Louis, MO, USA) dissolved in PBS, for 10 min at
RT, and then in the same solution containing 1 mLo f3 %H 2O2
per mL of DAB medium. The DAB reaction was interrupted at
times chosen by inspection of trial sections (approximately
5 min). Control sections were routinely processed by either
omitting the primary antibody or replacing it with an equivalent
concentration of rabbit IgG. After the DAB reaction, histological
sections were washed in PBS, mounted and dehydrated for light
microscopy visualization. Histological sections were finally
examined with a Zeiss Axiophot II microscope (Zeiss Iberica,
Madrid, Spain) and images captured with a digital camera
(DMC Ie, Polaroid, Cambridge, MA, USA).
CHO cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 1 mM sodium Pyruvate, 2 mM L-glutamine,
100 U/mL streptomycin, 100 mg/mL penicillin and 10% (v/v)
fetal bovine serum at 37uC in 95% air/5% CO2. Transfection of
CHO cells with siRNA targeting mouse RGSZ2 and control
siRNA was performed in LabTek 8-well chambers, with cells at
70–90% confluence, using siRNA transfection reagent following
the manufacturer’s instructions. The final concentration of the
vector in the medium was 1 mg. The transfection efficiencies were
estimated using a control siRNA fluorescein conjugate. The cells
were evaluated by PCR and immunocytochemistry 48–72 h after
transfection. For protein detection the cells were fixed with
methanol and the RGSZ2 expression was analyzed by immuno-
cytochemistry using the anti-RGSZ2 antibody (IQ 1:200, 2h,
room temperature) detected for 1h with an Alexa-conjugated goat
anti-rabbit (1:300; Molecular Probes, UK). After washing, cells
were counterstained with DAPI and visualized on a Leica DMIII
6000 CS confocal fluorescence microscope equipped with a TCS
SP5 scanning laser.
Total RNA was extracted from mouse brain, control cultures,
siRNA transfected and siRNA control using the Illustra RNAspin
Mini RNA isolation kit from GE Healthcare (Buckinghamshire,
UK). Equal amounts of RNA were reverse transcribed using the
First Strand Synthesis kit from Fermentas following the manu-
facturer instructions. Two different sets of primers were used,
the sequences were the following, primers pair 1: GTTCGC-
GATCGCCTGGTCTCAGAATTTTGACAAGATG (forward);
GATGGTTTAAACTTAGGATTCAGAAGTACAGCTGG (re-
verse); product length 418 bp; and primers pair 2: CTGAAGC-
CATGGACATGAGAAAACGG (forward); GCTGACCTCTT-
TCGGTGACTGTATAGAAATGT (reverse); product length 464
bp. Experiments were performed in Mastercycler (Eppendoorf)
with 35 cycles as follows: 95uC for 20 s, 58uC for 20 s, and 68uC
for 40 s after pre-incubation at 95uC for 2 min. PCR products
were separated on 2.5% agarose gel with SYBR Safe
TM DNA gel
stain to verify the expected product sizes.
Quantitative real-time polymerase chain reaction (PCR)
After reverse transcription (RT), the cDNA was diluted 1:3 in
nuclease-free water and used as template. RT-qPCR reactions
were performed with SYBR green dye technique in a total volume
of 20 ml using SYBR Green master mix in an ABI Prism 7500
Sequence Detector (Applied Biosystems) with conventional cycling
parameters. Primer sequences designed using Primer Express
(Applied Biosystems) were: CCCAACAATACCTGCTGCTTCT
and GGACCTGGATGCTCTCCATTT. Glyceraldehyde 3-
phosphate dehydrogenase (GADPH) was selected as control
housekeeping gene. Melting curve analysis of each sample was
performed after every run by defined heating up to 95uC to assess
the presence of unspecific PCR products. For each biological
replicate dual replicates were run. A minus RT control (RT-ve)
was included in each assay run besides a negative water control
reaction to assess for a possible contamination in the samples. All
reactions were performed in triplicate and the quantities of target
gene expression were normalized to the corresponding GAPDH
expression in test samples and plotted.
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All data were expressed as the mean6SEM. Comparisons of the
means between the experimental groups were performed with
ANOVA followed by the Student-Newman-Keuls test. Differences
with a P value of ,0.05 were considered significant.
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